Skip to main navigation Skip to search Skip to main content

Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals

  • Philip M. Grant
  • , Douglas Kitch
  • , Grace A. McComsey
  • , Ann C. Collier
  • , Susan L. Koletar
  • , Kristine M. Erlandson
  • , Michael T. Yin
  • , Benedetta Bartali
  • , Belinda Ha
  • , Kathy Melbourne
  • , Todd T. Brown

Research output: Contribution to journalArticlepeer-review

Abstract

We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5 years after antiretroviral therapy (ART) initiation and HIV-uninfected controls. HIV-infected individuals (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96 weeks of ART. Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate of decline in HIV-uninfected individuals at the lumbar spine but not at the hip. In HIV-infected individuals after 96 weeks, no HIV-or treatment-related characteristic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at both lumbar spine and hip.

Original languageEnglish (US)
Pages (from-to)607-611
Number of pages5
JournalJournal of Infectious Diseases
Volume214
Issue number4
DOIs
StatePublished - Aug 15 2016

Keywords

  • Administration and dosage
  • Adverse effects
  • Anti-HIV agents
  • Bone density
  • Drug therapy/virology
  • HIV infections

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals'. Together they form a unique fingerprint.

Cite this